Liver Diseases  >>  Ganovo (danoprevir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ganovo (danoprevir) / Roche, Ascletis, Pfizer
NCT00963885 / 2009-009608-38: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Checkmark
Jul 2013 - Jul 2013: 
Checkmark AASLD 2011: ATLAS
Oct 2011 - Oct 2011: AASLD 2011: ATLAS
Completed
2
229
US, Canada, Europe, RoW
Copegus, Pegasys, Placebo, RO5190591 (Danoprevir)
Hoffmann-La Roche
Hepatitis C, Chronic
01/12
01/12
NCT01331850 / 2010-019585-90: A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Checkmark MATTERHORN
Sep 2014 - Sep 2014: MATTERHORN
Checkmark AASLD 2012: MATTERHORN
Oct 2012 - Oct 2012: AASLD 2012: MATTERHORN
Completed
2
381
US, Canada, Europe, RoW
Copegus, Pegasys, RO5024048, danoprevir, ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
01/13
01/13
NCT01483742 / 2011-004129-28: A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Completed
2
43
US, Canada, Europe, RoW
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
09/13
09/13
ANNAPURNA, NCT01628094 / 2012-000638-21: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Checkmark APASL 2014: ANNAPURNA
Mar 2014 - Mar 2014: APASL 2014: ANNAPURNA
Checkmark AASLD 2013: ANNAPURNA
Oct 2013 - Oct 2013: AASLD 2013: ANNAPURNA
Completed
2
110
US, Europe, RoW
RO5024048, RO5190591, RO5466731, ribavirin [Copegus], ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
11/13
11/13
NCT01579019: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Withdrawn
2
0
US
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
03/14
03/14
NCT01749150: A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Completed
2
61
RoW
danoprevir + ritonavir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
Hoffmann-La Roche
Hepatitis C, Chronic
02/15
02/15

Download Options